Chronic myelogenous leukemia: effect of interferon-alpha treatment on phagocytic activity and capacity of circulating...

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome.
• Polymorphonuclear neutrophils (PMNs) play a crucial role in innate immunity through phagocytosis.
• Impaired PMN function is observed in various hematological malignancies, potentially affecting patient outcomes.

Purpose of the Study:

• To investigate the impact of interferon-alpha (IFN-alpha) on the phagocytic activity and capacity of PMNs in CML patients.
• To compare PMN phagocytosis in untreated CML, IFN-alpha treated CML with Ph1 chromosome persistence, and IFN-alpha treated CML with Ph1 conversion.
• To assess the efficacy of IFN-alpha treatment in restoring PMN phagocytic function in chronic phase CML.

Main Methods:

• Flow cytometry was utilized to quantify PMN phagocytosis.
• FITC-labeled Escherichia coli were used as target bacteria for phagocytosis assays.
• PMN samples were obtained from healthy donors, untreated CML patients, and IFN-alpha treated CML patients.

Main Results:

• PMN phagocytic activity and capacity were significantly reduced in untreated CML patients.
• Reduced phagocytic parameters were also observed in IFN-alpha treated CML patients with persistent Ph1 chromosome.
• Normal PMN phagocytic performance was restored in IFN-alpha treated CML patients who achieved Ph1 chromosome conversion.

Conclusions:

• IFN-alpha treatment can restore impaired PMN phagocytosis in CML patients.
• Successful IFN-alpha therapy, leading to Ph1 chromosome conversion, is associated with improved PMN immune function.
• Restoration of phagocytic capacity in PMNs suggests a potential mechanism for improved host defense in treated CML patients.